Bionxt completes Track One patent filing for BNT23001

Executive Summary

• Bionxt Solutions Inc. completed a U.S. “Track One” priority patent filing for its sublingual thin‑film cladribine formulation (BNT23001) targeting multiple sclerosis.
• The fast‑track filing secures accelerated examination, with an USPTO office action expected in 60–90 days and final disposition within 9–12 months, strengthening IP ahead of pivotal studies and partnership talks.
• Parallel national filings are progressing in major markets (EU, Canada, Australia, Eurasia, New Zealand, Japan) with favorable feedback from the European and Eurasian Patent Offices.

Key Details

• Patent Scope: Covers sublingual thin‑film cladribine for MS and extends to other neurological autoimmune diseases such as myasthenia gravis and lupus nephritis.
• USPTO Track One Process: Fast‑track priority examination; formal office action anticipated within 60–90 days; final patent disposition projected in 9–12 months.
• Global Nationalization: Patent applications underway in the EU, US, Canada, Australia, Eurasia, New Zealand, and Japan. European and Eurasian offices issued favorable communications, indicating intent to grant pending minor formalities.
• Strategic Impact: Enhances Bionxt’s IP position ahead of upcoming bioequivalence studies and commercial partnering discussions for BNT23001.
• Technology Description: BNT23001 is an orally dissolvable thin‑film formulation of cladribine designed for sublingual delivery, aiming to improve bioavailability, speed onset, and increase patient compliance—particularly for patients with dysphagia or who prefer non‑invasive dosing.

Notable Quotes

• “This fast‑track status represents a strategic opportunity to secure near‑term U.S. patent protection and strengthen the company’s IP position ahead of pivotal bioequivalence studies and commercial partnering discussions.” – Hugh Rogers, President & CEO, Bionxt Solutions Inc.